C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 3, Pages 272
Publisher
MDPI AG
Online
2019-03-27
DOI
10.3390/cells8030272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
- (2016) NATURE MEDICINE
- The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance
- (2016) Katarzyna Miekus ONCOLOGY REPORTS
- Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
- (2016) Boram Kim et al. PHYTOTHERAPY RESEARCH
- Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
- (2016) I. Duran et al. Targeted Oncology
- MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
- (2016) Stephan Macher-Goeppinger et al. Oncotarget
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- MET receptor is a potential therapeutic target in high grade cervical cancer
- (2015) Katarzyna Miekus et al. Oncotarget
- Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression
- (2015) Klaudia Skrzypek et al. Oncotarget
- MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
- (2015) Brian Shuch et al. Biomed Research International
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
- (2014) Zofia Bielecka et al. Current Signal Transduction Therapy
- Evolution of acquired resistance to anti-cancer therapy
- (2014) Jasmine Foo et al. JOURNAL OF THEORETICAL BIOLOGY
- Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
- (2014) R. Adelaiye et al. MOLECULAR CANCER THERAPEUTICS
- Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
- (2014) E. Ciamporcero et al. MOLECULAR CANCER THERAPEUTICS
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis
- (2014) Shoichiro Mukai et al. Human Cell
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
- (2013) Omid Hamid et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation
- (2013) K Miekus et al. Cell Death & Disease
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells
- (2012) ATSUSHI MATSUMURA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
- (2011) Pankaj Bhargava et al. Current Oncology Reports
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- Prognostic factors in a prospective series of papillary renal cell carcinoma
- (2008) Paolo Gontero et al. BJU INTERNATIONAL
- Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?
- (2008) Elizabeth Charytonowicz et al. CANCER LETTERS
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- Epithelial-Mesenchymal Transition in Cervical Cancer: Correlation with Tumor Progression, Epidermal Growth Factor Receptor Overexpression, and Snail Up-Regulation
- (2008) M.-Y. Lee et al. CLINICAL CANCER RESEARCH
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma
- (2008) W. Marston Linehan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
- (2008) X. Li et al. JNCI-Journal of the National Cancer Institute
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started